Imeglimin lowers CVD risk by improving postprandial flow-mediated dilation among diabetes patients

Imeglimin was given to participants in this trial who had type 2 diabetes and a HbA1c of less than 6.5% but were not taking insulin treatment. Before and three months after injection, a meal tolerance test (592 kcal, 75.0 g of glucose, and 28.5 g of fat) was conducted, and blood sugar, glucagon, endothelium function insulin, and triglycerides were measured. Flow-mediated dilation was used to evaluate endothelial function.

The key findings of this study were:

Twelve patients, with a median age of 55.5 years (having interquartile range [IQR] of 51.3-66.0) and a gender ratio of 50% male, were enrolled. 

Although there were no differences in fasting FMD before or 3 months after imeglimin treatment, 2 h postprandial FMD had dramatically improved. Imeglimin treatment improved significantly HbA1c, fasting glucose, and 2 h postprandial glucose in terms of the glucose profile. 

In a univariate correlation coefficient analysis, the difference in 2 h postprandial FMD between before and 3 months after imeglimin treatment (2 h postprandial FMD) was inversely linked with 2 h postprandial glucose. 

Three months after taking imeglimin, patients' postprandial FMD had improved in both patients with and without lowered postprandial glucose.

Reference: 

Uchida, T., Ueno, H., Konagata, A., Taniguchi, N., Kogo, F., Nagatomo, Y., Shimizu, K., Yamaguchi, H., & Shimoda, K. (2023). Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study. In Diabetes Therapy. Springer Science and Business Media LLC. https://doi.org/10.1007/s13300-023-01370-z